A recent study found that Vemurafenib-resistant melanoma was susceptible to BRD4 degradation [63], and bromodomain inhibitors such as OTX015 and BI-2536 have already had some success in treating carcinomas [80]. This evidence concerns the gene BRD4 and carcinoma.